SCHEMBL10043965

SCHEMBL10043965

Cc1cc2c(cn1)cc(-c1cc(NC(=O)C3CC=CN3C)ccc1C)c(=O)n2C

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 11/20 0.39
SYK P43405 1/20 0.39
MAPK14 Q16539 3/20 0.36
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
HPGD P15428 1/20 0.35
HSD17B10 Q99714 1/20 0.35
MAPK13 O15264 1/20 0.34
RAF1 P04049 1/20 0.34
PDGFRA P16234 1/20 0.34
MAPKAPK2 P49137 1/20 0.34
MAPK12 P53778 1/20 0.34
KCNH2 Q12809 1/20 0.34
MAPK11 Q15759 1/20 0.34
LCK P06239 1/20 0.34
KIT P10721 1/20 0.34
KDR P35968 1/20 0.34
FGFR4 P22455 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10043963 0.85 ABL1 (0.53) ABL1KDM4EALDH1A1HPGDHSD17B10
SCHEMBL14144989 0.84 CYP3A4 (0.43) ABL1SYKMAPK14KDM4EALDH1A1
SCHEMBL10043964 0.83 ABL1 (0.47) ABL1SYKKDM4EALDH1A1HPGD
SCHEMBL10043701 0.82 KDM4E (0.56) ABL1MAPK14KDM4EALDH1A1HPGD
SCHEMBL10043738 0.82 KDM4E (0.56) ABL1MAPK14KDM4EALDH1A1HPGD
SCHEMBL14217208 0.82 ABL1 (0.38) ABL1SYKMAPK14KDM4EALDH1A1
SCHEMBL10043968 0.81 ABL1 (0.48) ABL1KDM4EALDH1A1HPGDHSD17B10
SCHEMBL10043828 0.81 RAB9A (0.48) ABL1SYKMAPK14KDM4ERAF1
SCHEMBL14217004 0.80 ABL1 (0.39) ABL1SYKMAPK14KDM4EALDH1A1
SCHEMBL14217005 0.80 ABL1 (0.39) ABL1SYKMAPK14KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8106068-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2012-01-31 US disclosed
US-8106068-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2012-01-31 US disclosed
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2010-04-01 US disclosed
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2010-04-01 US disclosed
US-7678792-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2010-03-16 US disclosed
US-7678792-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2010-03-16 US disclosed
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2008-07-24 US disclosed
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2008-07-24 US disclosed
WO-2008051757-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2008-05-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS FYN, FLT3, SRC ABL1 59/4885SYK 42/4885MAPK14 117/4885
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS FYN, FLT3, SRC ABL1 59/4885SYK 42/4885MAPK14 117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.